GLS and non-small cell lung carcinoma: Finally, a potent, selective inhibitor of glutaminase, CB-839 is being tested in patients with colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, and melanoma (NCT03263429, NCT03831932, NCT02771626).